Literature DB >> 9342559

Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

J Hayashi1, S Kashiwagi.   

Abstract

Chronic infection with the hepatitis C virus (HCV) occurs throughout the world and appears to be the main cause of hepatocellular carcinoma. Studies have shown that, in areas of high endemicity, the prevalence of HCV infection is low in children but high in people aged > 60 years. Medical interventions were found to play an important role in the spread of HCV infection, because elderly patients became infected via contaminated blood transfusions or when contaminated syringes and needles were used. Maternal and sexual transmission do not appear to be the main routes of HCV infection. Interferon treatment eliminates HCV in 20 to 30% of patients with chronic HCV infection. The response to interferon therapy is usually complete in 70 to 80% of people with low levels of HCV RNA, HCV of genotype 2 and young women, but poor in elderly patients. Because liver disease can be severe in elderly patients, more effective therapies are clearly needed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342559     DOI: 10.2165/00002512-199711040-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  100 in total

1.  The prevalence of hepatitis C virus antibodies among hemodialysis patients.

Authors:  J B Zeldis; T A Depner; I K Kuramoto; R G Gish; P V Holland
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

2.  Prevalence of anti-HCV antibody in blood donors in the Tokyo area.

Authors:  J Watanabe; K Minegishi; T Mitsumori; M Ishifuji; T Oguchi; M Ueda; E Tokunaga; E Tanaka; K Kiyosawa; S Furuta
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

3.  Antibody to hepatitis C virus in German blood donors.

Authors:  P Kühnl; S Seidl; W Stangel; J Beyer; W Sibrowski; J Flik
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

4.  Nosocomial transmission of hepatitis C virus in haemodialysis patients.

Authors:  X de Lamballerie; M Olmer; D Bouchouareb; C Zandotti; P De Micco
Journal:  J Med Virol       Date:  1996-08       Impact factor: 2.327

5.  The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study.

Authors:  D B Brettler; P M Mannucci; A Gringeri; J E Rasko; A D Forsberg; M G Rumi; R J Garsia; K A Rickard; M Colombo
Journal:  Blood       Date:  1992-07-15       Impact factor: 22.113

6.  Improved detection of antibodies to hepatitis C virus by the second-generation assay in patients with chronic non-A, non-B liver disease.

Authors:  J Hayashi; K Nakashima; Y Kishihara; M Ohmiya; E Yoshimura; M Hirata; S Kashiwagi
Journal:  J Infect       Date:  1993-05       Impact factor: 6.072

7.  The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis.

Authors:  G Bresci; L Del Corso; A M Romanelli; G Giuliano; F Pentimone
Journal:  J Am Geriatr Soc       Date:  1993-08       Impact factor: 5.562

8.  A helper T-cell antigen enhances generation of hepatitis C virus-specific cytotoxic T lymphocytes in vitro.

Authors:  H Kita; T Moriyama; T Kaneko; K Hiroishi; I Harase; H Miura; I Nakamura; H Inamori; T Kodama; S Ohnishi
Journal:  J Med Virol       Date:  1995-04       Impact factor: 2.327

9.  Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.

Authors:  M Milella; G Antonelli; T Santantonio; M Currenti; L Monno; N Mariano; G Angarano; F Dianzani; G Pastore
Journal:  Liver       Date:  1993-06

10.  Clinicopathological features of hepatocellular carcinoma--comparison of hepatitis B seropositive and seronegative patients.

Authors:  H Okuda; H Obata; Y Motoike; T Hisamitsu
Journal:  Hepatogastroenterology       Date:  1984-04
View more
  1 in total

1.  Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.

Authors:  N Furusyo; J Hayashi; M Ohmiya; Y Sawayama; Y Kawakami; I Ariyama; N Kinukawa; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.